|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 7 (October 1), 1998:
pp. 2315-2321
A Special Fluorescent In Situ Hybridization Technique to Study
Peripheral Blood and Assess the Effectiveness of Interferon Therapy in
Chronic Myeloid Leukemia
Ismael Buño,
William A. Wyatt,
Alan R. Zinsmeister,
Jeanne Dietz-Band,
Richard T. Silver, and
Gordon W. Dewald
From the Division of Laboratory Genetics and Section of
Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, MN; Oncor,
Inc, Gaithersburg, MD; and the Chronic Myeloid Leukemia National Study
Group, Co-ordinating Center, New York Hospital-Cornell Medical Center,
New York, NY.
Using a highly sensitive fluorescence in situ hybridization method
with probes for BCR and ABL1 (D-FISH), we studied 37 paired sets of
bone marrow and blood specimens, collected within 24 to 96 hours of
each other, from 10 patients before and during treatment for chronic
myeloid leukemia (CML). The normal range for 500 interphase nuclei was
 4 (0.8%) nuclei based on 10 bone marrow and 10 blood specimens
from normal individuals. The percentage of neoplastic nuclei was
usually lower in blood than bone marrow. However, changes in the
percentage of neoplastic nuclei in blood and bone marrow tracked
closely over the course of therapy and with the results of quantitative
cytogenetic studies on bone marrow. This result indicates that D-FISH
is useful to test blood from patients with CML to monitor therapy.
Moreover, by analysis of 6,000 nuclei with D-FISH, residual disease was
identified in bone marrow and blood for patients in complete
cytogenetic remission. Consequently, D-FISH analyses of interphase
nuclei from blood could substitute for Q-cytogenetic studies on bone
marrow. Thus, it may not be necessary to collect bone marrow samples so
frequently to monitor therapy in CML.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogeneic transplantation for chronic myeloid leukemia
- Michael Deininger, Tornalf Lehmann, Rainer Krahl, Eveline Hennig, Christel Müller, Dietger Niederwieser;, Françoise Brizard, Andre Brizard, Françoise Guilhot, Jean-Claude Chomel, and Alain Kitzis
Blood 2000 96: 778-780.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
T S K Wan, S K Ma, W Y Au, and L C Chan
Derivative chromosome 9 deletions in chronic myeloid leukaemia: interpretation of atypical D-FISH pattern
J. Clin. Pathol.,
June 1, 2003;
56(6):
471 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Nashed, K. W. Rao, and M. L. Gulley
Clinical Applications of BCR-ABL Molecular Testing in Acute Leukemia
J. Mol. Diagn.,
May 1, 2003;
5(2):
63 - 72.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kolomietz, J. Al-Maghrabi, S. Brennan, J. Karaskova, S. Minkin, J. Lipton, and J. A. Squire
Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis
Blood,
June 1, 2001;
97(11):
3581 - 3588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Deininger, T. Lehmann, R. Krahl, E. Hennig, C. Muller, D. Niederwieser;, F. Brizard, A. Brizard, F. Guilhot, J.-C. Chomel, et al.
No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogeneic transplantation for chronic myeloid leukemia
Blood,
July 15, 2000;
96(2):
778 - 780.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Le Gouill, P. Talmant, N. Milpied, A. Daviet, M. Ancelot, P. Moreau, J.-L. Harousseau, R. Bataille, and H. Avet-Loiseau
Fluorescence In Situ Hybridization on Peripheral-Blood Specimens Is a Reliable Method to Evaluate Cytogenetic Response in Chronic Myeloid Leukemia
J. Clin. Oncol.,
April 7, 2000;
18(7):
1533 - 1538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Chomel, F. Brizard, A. Veinstein, J. Rivet, A. Sadoun, A. Kitzis, F. Guilhot, and A. Brizard
Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation
Blood,
January 15, 2000;
95(2):
404 - 408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, M. Talpaz, Z. Estrov, S. O'Brien, R. Kurzrock, and H. M. Kantarjian
The Biology of Chronic Myeloid Leukemia
N. Engl. J. Med.,
July 15, 1999;
341(3):
164 - 172.
[Full Text]
[PDF]
|
|
|
|
|
